Literature DB >> 26222892

N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia.

Rui Zhang1, Jiyuan Yang1, Yan Zhou1, Paul J Shami1,2, Jindřich Kopeček3,4.   

Abstract

There is a need for new treatment strategies of acute myeloid leukemia (AML). In this study, four different drugs, including cytarabine, daunorubicin, GDC-0980, and JS-K, were investigated in vitro for the two-drug combinations treatment of AML. The results revealed that cytarabine and GDC-0980 had the strongest synergism. In addition, cell cycle analysis was conducted to investigate the effect of the different combinations on cell division. For future in vivo application, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-cytarabine and GDC-0980 conjugates were synthesized, respectively. In vitro studies demonstrated that both conjugates had potent cytotoxicity and their combination also showed strong synergy, suggesting a potential chemotherapeutic strategy for future AML treatment.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  N-(2-hydroxypropyl)methacrylamide; acute myeloid leukemia; combination chemotherapy

Mesh:

Substances:

Year:  2015        PMID: 26222892      PMCID: PMC4805371          DOI: 10.1002/mabi.201500193

Source DB:  PubMed          Journal:  Macromol Biosci        ISSN: 1616-5187            Impact factor:   4.979


  49 in total

Review 1.  Clinical significance of P-glycoprotein in multidrug resistance malignancies.

Authors:  R J Arceci
Journal:  Blood       Date:  1993-05-01       Impact factor: 22.113

2.  Inhibition of NF-kappaB DNA binding by nitric oxide.

Authors:  J R Matthews; C H Botting; M Panico; H R Morris; R T Hay
Journal:  Nucleic Acids Res       Date:  1996-06-15       Impact factor: 16.971

3.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.

Authors:  M L Guzman; S J Neering; D Upchurch; B Grimes; D S Howard; D A Rizzieri; S M Luger; C T Jordan
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

4.  GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.

Authors:  Jeffrey J Wallin; Kyle A Edgar; Jane Guan; Megan Berry; Wei Wei Prior; Leslie Lee; John D Lesnick; Cristina Lewis; Jim Nonomiya; Jodie Pang; Laurent Salphati; Alan G Olivero; Daniel P Sutherlin; Carol O'Brien; Jill M Spoerke; Sonal Patel; Letitia Lensun; Robert Kassees; Leanne Ross; Mark R Lackner; Deepak Sampath; Marcia Belvin; Lori S Friedman
Journal:  Mol Cancer Ther       Date:  2011-10-13       Impact factor: 6.261

5.  JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism.

Authors:  Niharika Nath; Mitali Chattopadhyay; Liliya Pospishil; Lucyna Z Cieciura; Satindra Goswami; Ravinder Kodela; Joseph E Saavedra; Larry K Keefer; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2010-08-24       Impact factor: 5.858

6.  HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.

Authors:  T Minko; P Kopecková; V Pozharov; J Kopecek
Journal:  J Control Release       Date:  1998-07-31       Impact factor: 9.776

7.  Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.

Authors:  Bijan Moshaver; Anna van Rhenen; Angèle Kelder; Marjolein van der Pol; Monique Terwijn; Costa Bachas; August H Westra; Gert J Ossenkoppele; Sonja Zweegman; Gerrit Jan Schuurhuis
Journal:  Stem Cells       Date:  2008-12       Impact factor: 6.277

8.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.

Authors:  T C Chou; R J Motzer; Y Tong; G J Bosl
Journal:  J Natl Cancer Inst       Date:  1994-10-19       Impact factor: 13.506

Review 9.  Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1).

Authors:  C L Willman
Journal:  Leukemia       Date:  1996-04       Impact factor: 11.528

10.  Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.

Authors:  Alan K Burnett; Robert K Hills; Donald W Milligan; Anthony H Goldstone; Archibald G Prentice; Mary-Frances McMullin; Andrew Duncombe; Brenda Gibson; Keith Wheatley
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

View more
  2 in total

Review 1.  Design of smart HPMA copolymer-based nanomedicines.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

Review 2.  Recent advances in polymeric drug delivery systems.

Authors:  Yong Kiel Sung; Sung Wan Kim
Journal:  Biomater Res       Date:  2020-06-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.